cystic fibrosis
Vertex destroyed nearly 8,000 packs of Orkambi in 2018
March 28, 2019Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis
Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …
Vertex doubles Q4 profits, angering cystic fibrosis drug advocates in UK
February 11, 2019Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma
Despite ongoing controversy surrounding the currently stalled negotiations between Vertex and the NHS to make its cystic fibrosis (CF) drug …
Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission
January 22, 2019Manufacturing and Production, Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma
Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) …
Top Ten most popular articles on Pharmafile.com this week
April 13, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten
It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …
Top Ten most popular articles on Pharmafile.com this week
April 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Boehringer Ingelheim, Kite, Nordic Nanovector, Pfizer, Roche, Sanofi, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …
Transforming cystic fibrosis treatment
April 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …
Vertex “astonished” by NHS England’s response to CF drug
March 20, 2018Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Vertex has been battling to have its treatment, Orkambi, approved in the UK since 2016, when it was first rejected …
Vertex gets approval for combo-therapy in cystic fibrosis
February 13, 2018Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
All eyes are on Vertex’s two Phase 3 trials into a triple therapy for cystic fibrosis (CF), in the meantime, …
Decade lifespan difference in Americans and Canadians with cystic fibrosis
March 15, 2017Research and Development Canada, United States, cystic fibrosis
A new study has emerged looking into life expectancy of those with cystic fibrosis, funded by the US Cystic Fibrosis …
Vertex stumbles in Phase III cystic fibrosis trials
August 16, 2016Manufacturing and Production, Research and Development Vertex, cystic fibrosis, phase III
Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in …
Orkambi deemed not suitable for NHS use
July 27, 2016Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis
The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …
Synergy Vision MD appointed as trustee of the Cystic Fibrosis Trust
June 17, 2016Medical Communications Synergy Vision, appointment, cystic fibrosis, cystic fibrosis trust, medical communications, medical communications agency
Managing director of Synergy Vision Ffyona Dawber has been appointed to the Cystic Fibrosis Trust’s board of trustees. Her wealth …
Final Nice appraisal says no to cystic fibrosis drug, Orkambi
June 17, 2016Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …
Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco
May 10, 2016Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation
The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX). SMC did not recommend …
NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi
March 23, 2016Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis
NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
